AirView also now widely available for Astral life support ventilators, the first and only ventilator connectivity of its kind
ATLANTA, Nov. 1, 2016 /CNW/ -- ResMed (NYSE: RMD) today announced two enhancements to AirView™, the world's largest cloud-based remote patient monitoring platform that enables care teams to securely access therapy data from three million sleep apnea and respiratory care patients every day.
AirView Action Groups automatically filters a clinician's sleep apnea patients on positive airway pressure (PAP) therapy into actionable groups based on adherence status or a specific therapy issue they may be having. This new "manage by exception" feature will reduce the time clinicians spend on back-office paperwork and processes, and will help ensure that patients get the most responsive and quality treatment.
In addition, when home medical equipment (HME) and other healthcare providers are required to prove a patient's adherence before receiving reimbursement, they can now do so with greater efficiency. Action Groups are based on a similar feature in U-Sleep™ – another ResMed monitoring tool – that reduced clinicians' patient management time by 59%.
AirView for Astral™ is now widely available, giving physicians and HME providers access to key data from their high-acuity or life support ventilator patients in ResMed's secure cloud network. Clinicians can access their patient data in AirView or through the ResMed Data Exchange where they can integrate their system's electronic health records with AirView.
"Cloud connectivity is a major factor in the future of healthcare, but it's not enough," said Raj Sodhi, president of ResMed's healthcare informatics business unit. "With the launch of AirView Action Groups, and AirView for Astral now available worldwide, we're not only creating the connections and securely delivering the data to clinicians, we are providing them with the very specific and timely information they need about their patients – how they want it, when they want it and where they want it. ResMed's pioneering innovations in this area will continue to positively impact patient outcomes and providers' business efficiencies."
"The Action Groups make us incredibly more efficient," says Stephanie Gersten, president and owner of CPAP Success, a San Francisco Bay Area-based HME provider. "Our staff got back all the hours they used to spend identifying which patients need what kind of support. Now they just pick a therapy issue, click that Action Group to see who has that issue, and go from there."
"Cloud-connected ventilators means my staff can serve more patients, and also give them and their families greater peace of mind," said Chris Masek, RRT, Mechanical Ventilator Coordinator at Kubat Pharmacy in Omaha, NE. "There's a unique security that comes with Astral, knowing that a clinician can see what's happening with therapy miles away with the click of a button."
ResMed is demonstrating these latest AirView features and other connected care solutions today through November 3 at the annual Medtrade conference in Atlanta at Booth 1511 – along with its new line of AirFit™ 20 CPAP masks, also announced today.
ResMed plans to make the AirFit F20 and N20 masks available in the United States later this year (subject to clearance by the U.S. Food and Drug Administration). Both masks are currently being rolled out in Europe, the Middle East, Africa and Asia-Pacific.
ResMed (NYSE: RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 2 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world's best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.
ResMed.com | Facebook | Twitter | LinkedIn
Logo - http://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a
SOURCE ResMed Inc.